ponatinib,imatinib
takeda,otsuka,incyte
['ponatinib', 'leusm', 'imatinib']
congress | #asco23 | elias jabbour, shared the updated phase 3 phallcon results on ponatinib vs imatinib with low-dose chemo in nd pts with ph+all. primary endpoint was met: ponatinib yielded higher mrd-neg cr rates; safety profiles were comparable
#allsm #leusm 
A global education platform providing clinical updates on acute lymphoblastic leukemia. #leusm #allsm